Abstract
Completely resected non-small cell lung cancer (NSCLC) patients with histologically confirmed N2 disease are a heterogeneous population, with a 5-year overall survival (OS) in the range of 10-30%. After postoperative chemotherapy (POCT), 20%-40% of cases have a risk of locoregional recurrence (LRR). Due to a high degree of heterogeneity among IIIA(N2) disease, the value and optimal timing of postoperative radiotherapy (PORT) for completely resected stage IIIA(N2) NSCLC remains controversial. In this randomized clinical trial (RCT), we aimed to investigate the clinical efficacy of PORT for patients with low risk of LRR and investigate the optimal timing of PORT for those with high risk of LRR.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
